BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF‑κB pathway proteins

Lin,Shengyun; Li,Jing; Zhou,Wenjing; Qian,Wenbin; Wang,Bo; Chen,Zhi

doi:10.3892/etm.2014.1651

BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NF‑κB pathway proteins

Authors:
- Shengyun Lin
- Jing Li
- Wenjing Zhou
- Wenbin Qian
- Bo Wang
- Zhi Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310006, P.R. China, Institute of Hematology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China
Published online on: March 28, 2014 https://doi.org/10.3892/etm.2014.1651
Pages: 1539-1544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The novel orally available inhibitor of the molecular chaperone heat shock protein 90 (Hsp90), BIIB021, induces the apoptosis of various types of tumor cell in vitro and in vivo. However, the effects and mechanisms of this agent on myelodysplastic syndrome (MDS) cell lines remain unknown. The aim of this study was to investigate the effects of BIIB021 on SKM‑1 cells (a MDS cell line) and examine its mechanisms of action. The results showed that BIIB021 inhibited the growth of SKM‑1 cells effectively in vitro. The treatment of SKM‑1 cells with BIIB021 resulted in the inhibition of cell growth through G0/G1‑phase cell cycle arrest and induced apoptosis by activating caspase‑3, ‑8 and ‑9. Furthermore, this study also demonstrated that the mechanisms of apoptosis in SKM‑1 cells were associated with the suppression of the phosphatidylinositide 3‑kinase/Akt and nuclear factor‑κB signaling pathways. Therefore, the findings indicate a novel approach for the treatment of high‑risk MDS.

View Figures

View References

1	Cogle CR, Craig BM, Rollison DE and List AF: Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 117:7121–7125. 2011. View Article : Google Scholar : PubMed/NCBI
2	Tefferi A and Vardiman JW: Myelodysplastic syndromes. N Engl J Med. 361:1872–1885. 2009. View Article : Google Scholar
3	Komrokji RS, Corrales-Yepez M, Al Ali N, et al: Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome. Cancer. 118:2659–2664. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sekeres MA, Schoonen WM, Kantarjian H, List A, Fryzek J, Paquette R and Maciejewski JP: Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst. 100:1542–1551. 2008. View Article : Google Scholar : PubMed/NCBI
5	Fukumoto JS and Greenberg PL: Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 56:179–192. 2005. View Article : Google Scholar : PubMed/NCBI
6	Gore SD and Hermes-DeSantis ER: Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes. Cancer Control. 16(Suppl): 2–10. 2009.PubMed/NCBI
7	Szmigielska-Kapłon A and Robak T: Hypomethylating agents in the treatment of myelodysplastic syndromes and myeloid leukemia. Curr Cancer Drug Targets. 11:837–848. 2011.PubMed/NCBI
8	Garcia-Manero G: Treatment of higher-risk myelodysplastic syndrome. Semin Oncol. 38:673–681. 2011. View Article : Google Scholar : PubMed/NCBI
9	Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC and Burrows FJ: A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
10	Yufu Y, Nishimura J and Nawata H: High constitutive expression of heat shock protein 90 alpha in human acute leukemia cells. Leuk Res. 16:597–605. 1992. View Article : Google Scholar : PubMed/NCBI
11	Flandrin P, Guyotat D, Duval A, Cornillon J, Tavernier E, Nadal N and Campos L: Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells. Cell Stress Chaperones. 13:357–364. 2008. View Article : Google Scholar : PubMed/NCBI
12	Duval A, Olaru D, Campos L, Flandrin P, Nadal N and Guyotat D: Expression and prognostic significance of heat-shock proteins in myelodysplastic syndromes. Haematologica. 91:713–714. 2006.PubMed/NCBI
13	Flandrin-Gresta P, Solly F, Aanei CM, et al: Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase. Oncotarget. 3:1158–1168. 2012.PubMed/NCBI
14	Didelot C, Lanneau D, Brunet M, Joly AL, De Thonel A, Chiosis G and Garrido C: Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. Curr Med Chem. 14:2839–2847. 2007. View Article : Google Scholar : PubMed/NCBI
15	Kaufmann SH, Karp JE, Litzow MR, et al: Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 96:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI
16	Jhaveri K, Taldone T, Modi S and Chiosis G: Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755. 2012. View Article : Google Scholar : PubMed/NCBI
17	Taldone T, Gozman A, Maharaj R and Chiosis G: Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol. 8:370–374. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lundgren K, Zhang H, Brekken J, et al: BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
19	Dickson MA, Okuno SH, Keohan ML, et al: Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol. 24:252–257. 2013. View Article : Google Scholar : PubMed/NCBI
20	Huang M, Zhang H, Liu T, Tian D, Gu L and Zhou M: Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a P53-independent pathway. Mol Cancer Ther. 12:184–194. 2013. View Article : Google Scholar : PubMed/NCBI
21	Nyåkern M, Tazzari PL, Finelli C, et al: Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia. 20:230–238. 2006.PubMed/NCBI
22	Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferquson DO, Wu H and Morrison SJ: Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 441:475–482. 2006. View Article : Google Scholar : PubMed/NCBI
23	Guo W, Lasky JL, Chang CJ, et al: Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature. 453:529–533. 2008. View Article : Google Scholar : PubMed/NCBI
24	Breccia M and Alimena G: NF-κB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets. 14:1157–1176. 2010.
25	Cilloni D, Martinelli G, Messa F, Baccarani M and Saglio G: Nuclear factor κB as a target for new drug development in myeloid malignancies. Haematologica. 92:1224–1229. 2007.
26	Liu KS, Zhang Y, Ding WC, et al: The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human esophageal squamous carcinoma cells. Int J Oncol. 41:2276–2284. 2012.PubMed/NCBI
27	Calderwood SK, Khaleque MA, Sawyer DB and Ciocca DR: Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 31:164–172. 2006. View Article : Google Scholar : PubMed/NCBI
28	Mjahed H, Girodon F, Fontenay M and Garrido C: Heat shock proteins in hematopoietic malignancies. Exp Cell Res. 318:1946–1958. 2012. View Article : Google Scholar : PubMed/NCBI
29	Jego G, Hazoumé A, Seigneuric R and Garrido C: Targeting heat shock proteins in cancer. Cancer Lett. 332:275–285. 2013. View Article : Google Scholar : PubMed/NCBI
30	Neckers L and Workman P: Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 18:64–76. 2012. View Article : Google Scholar : PubMed/NCBI
31	Chiosis G, Lucas B, Huezo H, Solit D, Basso A and Rosen N: Development of purine-scaffold small molecule inhibitors of Hsp90. Curr Cancer Drug Targets. 3:371–376. 2003. View Article : Google Scholar : PubMed/NCBI
32	Braun T, Carvalho G, Fabre C, Grosjean J, Fenaux P and Kroemer G: Targeting NF-kappaB in hematologic malignacies. Cell Death Differ. 13:748–758. 2006. View Article : Google Scholar : PubMed/NCBI
33	Kerbauy DM, Lesnikov V, Abbasi N, Seal S, Scott B and Deeq HJ: NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood. 106:3917–3925. 2005. View Article : Google Scholar : PubMed/NCBI
34	Chapuis N, Tamburini J, Cornillet-Lefebvre P, et al: Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica. 95:415–423. 2010. View Article : Google Scholar
35	He Q, Li X, Zhang Z, et al: Overexpression of IGF-IR in malignant clonal cells in bone marrow of myelodysplastic syndromes. Cancer Invest. 28:983–988. 2010. View Article : Google Scholar : PubMed/NCBI
36	Mendoza MC, Er EE and Blenis J: The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
37	Economopoulou C, Pappa V, Papageorgiou S, et al: Cell cycle and apoptosis regulatory gene expression in the bone marrow of patients with de novo myelodysplastic syndromes (MDS). Ann Hematol. 89:349–358. 2010. View Article : Google Scholar : PubMed/NCBI
38	Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 91:2985–2990. 1998.PubMed/NCBI
39	Chen G, Zeng W, Miyazato A, et al: Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 104:4210–4218. 2004. View Article : Google Scholar : PubMed/NCBI
40	Olnes MJ, Shenoy A, Weinstein B, et al: Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910. Na Leuk Res. 36:982–989. 2012. View Article : Google Scholar : PubMed/NCBI
41	Böll B, Eltaib F, Reiners KS, et al: Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin’s lymphoma cells for natural killer cell-mediated cytotoxicity. Clin Cancer Res. 15:5108–5116. 2009.PubMed/NCBI